JAZZ
Jazz Pharmaceuticals plc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Jazz Pharmaceuticals has 16 disclosed suppliers and 4 disclosed customers in SEC filings.
SentenceUnder the Jazz Collaboration Agreement, as of December 31, 2025 we have received (i) a non-refundable $50.0 million upfront payment following receipt of HSR Clearance and delivery of licenses and technology transfer to Jazz, (ii) a further payment of $325.0 million following Jazz's decision to continue the collaboration after readout of the top-line clinical data from HERIZON-BTC-01, in addition to our delivery of other data, analyses and other information, and (iii) a milestone payment of $25.0 million in relation to FDA approval of Ziihera (zanidatamab-hrii) for the treatment of HER2+ BTC.
SentenceModeyso is manufactured by Adare, which is a sole source supplier.
JAZZ 10-Kaccession 0001232524-26-000013
SentenceRylaze drug substance is manufactured by AGC Biologics A/S at its facility in Copenhagen, Denmark and the drug product is manufactured and packaged by Patheon at its facility in Greenville, North Carolina.
JAZZ 10-Kaccession 0001232524-26-000013
Sentence• Autifony to collaborate on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders;
JAZZ 10-Kaccession 0001232524-26-000013
SentenceWe completed the Chimerix Acquisition in April 2025 for a total of cash consideration of $944.2 million, adding Modeyso (dordaviprone), a protease activator of the mitochondrial ClpP that also inhibits DRD2, to our rare oncology portfolio.
JAZZ 10-Kaccession 0001232524-26-000013
SentenceWe depend on outside vendors, including ESSDS, the central certified pharmacy, to distribute Xywav and Xyrem in the U.S., provide patient support services and implement the requirements of the Xywav and Xyrem REMS.
JAZZ 10-Kaccession 0001232524-26-000013
SentenceRylaze drug substance is manufactured by AGC Biologics A/S at its facility in Copenhagen, Denmark and the drug product is manufactured and packaged by Patheon at its facility in Greenville, North Carolina.
JAZZ 10-Kaccession 0001232524-26-000013
SentenceOur exclusive U.S. development and commercialization rights to Zepzelca were acquired through an exclusive license agreement we entered into with PharmaMar in December 2019.
JAZZ 10-Kaccession 0001232524-26-000013
Sentence• Redx for preclinical collaboration activities related to G12D selective and pan-KRAS molecules that we purchased from Redx;
JAZZ 10-Kaccession 0001232524-26-000013
Sentence• Saniona to develop a small molecule activator of Kv7.2/Kv7.3 potassium channels for epilepsy and other potential indications;
JAZZ 10-Kaccession 0001232524-26-000013
SentenceZepzelca is manufactured by Simtra, which is a sole source supplier from a single site location.
JAZZ 10-Kaccession 0001232524-26-000013
SentenceIn May 2022, we announced that we had entered into a licensing agreement with Sumitomo to acquire exclusive development and commercialization rights in the U.S., Europe and other territories for JZP441.
JAZZ 10-Kaccession 0001232524-26-000013
SentenceWe acquired rights to JZP898 from Werewolf in 2022 under an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize Werewolf's investigational WTX-613, now referred to as JZP898.
JAZZ 10-Kaccession 0001232524-26-000013
SentenceWe currently rely on WuXi (Hong Kong), a company based in the PRC and subsidiary of WuXi, as the sole supplier of Ziihera.
JAZZ 10-Kaccession 0001232524-26-000013
Sentence• XLp for rights to use XLp's PASylation ® technology to extend the plasma half-life of selected asparaginase product candidates;
JAZZ 10-Kaccession 0001232524-26-000013
SentenceOur collaborator, Jazz Pharmaceuticals plc (Jazz), sponsored and managed the Phase 1b/2 trial of zanidatamab, a HER2-targeted anti-cancer antibody, for the treatment of advanced HER2-expressing breast cancer and other solid tumors in combination with evorpacept (Zanidatamab Trial).
SentenceIn May 2022, the Company acquired the U.S. rights to SUNOSI ® (solriamfetol) from Jazz Pharmaceuticals plc ("Jazz"), and in November 2022, the Company acquired worldwide ex-U.S. rights (excluding certain Asian markets) from Jazz (collectively, the "Acquisition").
SentenceIn October 2025, we divested Sativex to CNX Therapeutics, who will assume responsibility for Sativex in all countries it is approved.
JAZZ 10-Kaccession 0001232524-26-000013
SentenceWe are also paid for supply of the Hikma AG product and are reimbursed by Hikma for a portion of the services costs associated with the operation of the Xywav and Xyrem REMS, and distribution of the Hikma AG product.
JAZZ 10-Kaccession 0001232524-26-000013
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Jazz Pharmaceuticals plc
214.55
Linked news
Expected move
Inputs8Q avg ±5.9%·×1.14·fair
straddle ±8.0%
spot 215.98exp Nov 20ATM strike 220ATM straddle 20.30IV 48%